Why would the ODAC meeting have been needed at all if the clinical trial evidence had actually "proven" efficacy. ODAC provided an opinion that it might have efficacy.
So I'm not sure where you get the idea that "potency" was the only issue. The CRL identified a range of issues.
Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-318
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.025(2.55%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 99.0¢ | $2.951M | 2.939M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 94 | 238082 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 23964 | 5 |
View Market Depth
| Last trade - 13.16pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |